

Multi-species biofilms: how to avoid unfriendly neighbors

Olaya Rendueles & Jean-Marc Ghigo

Institut Pasteur, Unité de Génétique des Biofilms, Paris, France

Correspondence: Jean-Marc Ghigo, Institut Pasteur, Unité de Génétique des Biofilms, 25-28 rue du Dr Roux, 75724 Paris Cedex 15, France. Tel.: +33 01 40 61 34 18; fax: +33 01 45 68 88 36; e-mail: jmghigo@pasteur.fr

Received 12 October 2011; revised 17 December 2011; accepted 22 December 2011. Final version published online 8 March 2012.

DOI: 10.1111/j.1574-6976.2012.00328.x

Editor: Dieter Haas

Keywords

biofilm formation; adhesion; bacterial interferences; mixed communities; biosurfactants; biofilm dispersion.

Introduction

In most environments, bacteria form multispecies communities and develop heterogeneous structures known as biofilms (Costerton *et al.*, 1987; Hall-Stoodley *et al.*, 2004). In contrast to liquid suspensions, the high cell density and reduced diffusion prevailing within biofilms provide opportunities for intense exchanges ranging from cooperation (for a detailed review of cooperative interactions see the accompanying paper by Elias and Banin appearing in this issue) to harsh competition (James *et al.*, 1995; Moons *et al.*, 2009). Such interactions can lead to physiological and regulatory alterations within biofilm bacteria, and this may eventually contribute to the selection of better adapted mutants. These interactions can influence the emergence and disappearance of species and therefore play an important role in the shaping of multi-species biofilm communities (Hibbing *et al.*, 2010; Dubey & Ben-Yehuda, 2011). Thus far, the studies of how bacteria relate to each other within these communities have often focused on antagonisms impairing fitness of bacterial competitors via, for instance, the production of toxins, scavenger molecules, and antimicrobials.

Abstract

Multi-species biofilm communities are environments in which complex but ill understood exchanges between bacteria occur. Although monospecies cultures are still widely used in the laboratory, new approaches have been undertaken to study interspecies interactions within mixed communities. This review describes our current understanding of competitive relationships involving nonbiocidal biosurfactants, enzymes, and metabolites produced by bacteria and other microorganisms. These molecules target all steps of biofilm formation, ranging from inhibition of initial adhesion to matrix degradation, jamming of cell–cell communications, and induction of biofilm dispersion. This review presents available data on nonbiocidal molecules and provides a new perspective on competitive interactions within biofilms that could lead to antibiofilm strategies of potential biomedical interest.

However, biofilm formation is a complex process involving multiple adhesion and dispersion events which, from initial surface contact to tri-dimensional maturation, can be shaped by microbial interactions that do not necessarily rely on growth-inhibiting molecules or processes (Fig. 1). Recently, the studies on mixed biofilm communities have shed light on a surprising diversity of nonbiocidal compounds targeting different stages of biofilm formation (Table 1). Although most of these compounds were first identified in monospecies cultures or studied in ecologically irrelevant experimental mixed species settings, they could be involved in biofilm population dynamics *in vivo*. This review describes how nonbiocidal molecules affect microbial interactions in biofilm environments and discusses their potential biological role and perspectives as alternative antibiofilm molecules of industrial and biomedical interest.

A cold welcome: Inhibition of initial adhesion

The first interactions between bacteria and surfaces are crucial for biofilm formation and, depending on the




Fig. 1. Antibiofilm molecules act at several stages of the biofilm formation process. Biofilm formation is often described as a multistep process in which bacteria adhere to an abiotic or biotic surface, through surface charges and production of pili, fimbriae, and exopolysaccharides. After initial attachment, three-dimensional development starts with the building of microcolonies, in which different species already interact. The next step, biofilm maturation, is dependent on matrix production, which ensures cohesion and the three-dimensional structure of mature biofilms (Flemming & Wingender, 2010a). Scanning electron microscopy images representative of each step are shown. The final step in biofilm formation is cellular detachment or dispersion, by which bacteria regain the planktonic lifestyle to colonize other surfaces. Microbial interferences can inhibit biofilm formation or enhance biofilm dispersion through different mechanisms and strategies at different stages of their development.

nature of the surface, can be driven by different mechanisms. Adhesion to abiotic surfaces, for instance, is often mediated by nonspecific events that primarily depend on cell-surface charge and hydrophobicity, the presence of extracellular polymers and organic conditioning film (Dunne, 2002). On the other hand, binding to biotic surfaces such as host tissues and mucosa epithelial cells can be mediated by specific receptors and influenced by host responses to bacterial colonization (Finlay & Falkow, 1989; Kline *et al.*, 2009). While environmental factors influence the initial steps of adhesion, bacterial activity *per se* has also been shown to alter the outcome of surface interactions through either production of antiadhesion molecules that modify surface physico-chemical properties, or composition of a physical bacterial barrier (surface 'blanketing') preventing surface contact with other competing bacteria.

Bacterial surface blanketing

One of the simplest strategies for avoiding initial colonization of competing strains is the rapid occupancy of all available adhesion sites, referred to as 'surface blanketing'.

This strategy is illustrated in competition experiments between *Pseudomonas aeruginosa* and *Agrobacterium tumefaciens* (An *et al.*, 2006). In a mixed species co-cultivation experimental model, *P. aeruginosa* rapidly spread through the surface via swarming and twitching motility, preventing *A. tumefaciens* adhesion. In contrast, a *P. aeruginosa* *flgK* motility-deficient mutant unable to spread quickly over a surface was no longer able to exclude *A. tumefaciens*, therefore allowing *A. tumefaciens* to form a mixed surface biofilm with *P. aeruginosa* (An *et al.*, 2006). Although this simple and intuitive strategy is often mentioned as a possible competition mechanism, the actual contribution of surface blanketing in interspecies interactions is currently not known.

Slippery surface: biosurfactant production

Bacteria have long been known to secrete biosurfactants altering surface properties such as wettability and charge (Neu, 1996; Banat *et al.*, 2010). The physiological roles of these surfactants, widespread among bacteria, are often unclear, but they generally weaken bacteria-surface and bacteria-bacteria interactions, therefore reducing the ability

Table 1. Biofilm-inhibiting molecules produced by other bacteria. Different colors indicate successive stages of the biofilm life cycle

Susceptible strain	Produced by	Molecule	Step inhibited	Mechanism of action	Molecular basis	Reference
Broad spectrum	<i>Escherichia coli</i> UPEC	Group II capsule	Initial adhesion	Alteration of cell-surface and cell-to cell interactions	<i>kps</i> region	Valle <i>et al.</i> (2006)
Broad spectrum	<i>Lactobacillus acidophilus</i>	EPS	Initial adhesion	Downregulation of curli (<i>cri</i> , <i>csgA</i> , and <i>csgB</i>) and chemotaxis	–	Kim <i>et al.</i> (2009)
<i>Streptococcus pyogenes</i>	Several marine bacteria	–	Initial adhesion	Reduction of cell-surface hydrophobicity	–	Nithyanand <i>et al.</i> (2010)
<i>Streptococcus pyogenes</i>	<i>Bacillus horikoshii</i>	–	Initial adhesion	QS inhibition	–	Thenmozhi <i>et al.</i> (2009)
<i>Vibrio spp.</i>	<i>Streptomyces albus</i>	–	Initial adhesion	QS inhibition	–	You <i>et al.</i> (2007)
Broad spectrum	<i>Bacillus pumilus</i> S6-15	4-phenylbutanoic acid	Initial adhesion	Reduces hydrophobicity index and EPS production	–	Nithya <i>et al.</i> (2011)
<i>Escherichia coli</i> CFT073	<i>Bacillus subtilis</i>	Biosurfactant	Initial adhesion	–	–	Rivardo <i>et al.</i> (2009)
Broad spectrum	<i>Bacillus licheniformis</i>	α -D-galactopyranosyl-(1→2)-glycerol-phosphate	Initial adhesion	Independent of quorum sensing	–	Sayem <i>et al.</i> (2011)
<i>Staphylococcus aureus</i>	<i>Bacillus licheniformis</i>	Biosurfactant	Initial adhesion	–	–	Rivardo <i>et al.</i> (2009)
<i>Streptococcus mutans</i>	<i>Streptococcus gordonii</i>	Challisin	Initial adhesion	QS inhibition	<i>sgc</i>	Wang <i>et al.</i> (2011)
<i>Streptococcus mutans</i>	<i>Streptococcus salivarius</i>	–	Initial adhesion	CSP inactivation by <i>glrA</i> -dependent susceptibility	–	Tamura <i>et al.</i> (2009)
Gram-positive bacteria, yeast	<i>Streptococcus thermophilus</i> A	Biosurfactant	Initial adhesion	Reduction of cell-surface hydrophobicity	–	Rodrigues <i>et al.</i> (2006b)
<i>Enterococcus faecalis</i>	<i>Lactobacillus</i>	Surlactin	Initial adhesion	–	–	Velraeds <i>et al.</i> (1996)
<i>Agrobacterium tumefaciens</i>	<i>Pseudomonas aeruginosa</i>	Small diffusible molecule	Initial adhesion	–	–	Mowat <i>et al.</i> (2010)
<i>Pseudomonas aeruginosa</i> PAO1	<i>Bacillus</i> spp. SS4	Nonenzymatic	Initial adhesion	QS inhibition	–	Musthafa <i>et al.</i> (2011)
Gram-positive bacteria	<i>Escherichia coli</i> Ec300/ <i> Klebsiella pneumoniae</i> 342	Mannose-rich polysaccharide	Initial adhesion	Alteration of cell-surface interactions	<i>galF-his</i> region	Rendueles <i>et al.</i> (2011)
Broad spectrum	<i>Kingella kingae</i>	PAM galactan	Initial adhesion	–	<i>pamABCDE</i>	Bendaoud <i>et al.</i> (2011)
<i>Streptococcus mutans</i>	<i>Enterococcus faecium</i>	Protein	Initial adhesion	–	–	Kumada <i>et al.</i> (2009)
<i>Salmonella enterica</i> , <i>Escherichia coli</i> , <i>Proteus mirabilis</i> and <i>Pseudomonas aeruginosa</i>	<i>Bacillus subtilis</i>	Surfactin	Initial adhesion	Alteration of cell-surface interactions	<i>sfp</i> locus	Mireles <i>et al.</i> (2001)
Broad spectrum	<i>Streptococcus phocae</i> P180	Biosurfactant	Initial adhesion	–	–	Kanmani <i>et al.</i> (2011)
Several marine bacteria	<i>Pseudoalteromonas</i> sp	–	–	–	–	Klein <i>et al.</i> (2011)

Table 1. Continued

Susceptible strain	Produced by	Molecule	Step inhibited	Mechanism of action	Molecular basis	Reference
<i>Staphylococcus epidermidis</i>	<i>Pseudomonas aeruginosa</i>	Psl and Pel polysaccharide	Initial adhesion and biofilm detachment	–	<i>Psl</i> and <i>pel</i> operons	Qin <i>et al.</i> (2009)
<i>Pseudomonas putida</i>	<i>Pseudomonas aeruginosa</i>	2-heptyl-3-hydroxy-4-quinolone (PQS)	Initial adhesion and biofilm dispersion	Upregulation of swarming motility	<i>pqsABCDE</i>	Fernandez-Pinar <i>et al.</i> (2011)
<i>Bacillus pumilus</i> TiO1	<i>Serratia marcescens</i>	Glycolipid	Initial adhesion and biofilm detachment	Alteration of surface properties	–	Dusane <i>et al.</i> (2011)
<i>Staphylococcus aureus</i>	<i>Staphylococcus epidermidis</i>	Serine protease Esp	Initial adhesion, biofilm detachment	–	<i>esp</i>	Iwase <i>et al.</i> (2010)
<i>Pseudomonas aeruginosa</i>	Marine bacteria	–	Initial adhesion and biofilm detachment	QS inhibition and reduces cell-surface hydrophobicity	–	Nithya <i>et al.</i> (2010a, b)
<i>Staphylococcus aureus</i> , <i>Staphylococcus epidermidis</i>	<i>Lactobacillus acidophilus</i>	Biosurfactant	Initial adhesion, biofilm development and detachment	–	–	Walencka <i>et al.</i> (2008a)
<i>Porphyromonas gingivalis</i>	<i>Streptococcus intermedius</i>	Arginine deiminase	Irreversible attachment	Downregulation of two different fimbria (<i>fimA</i> and <i>mfa1</i>)	–	Christopher <i>et al.</i> (2010)
Broad spectrum	<i>Pseudomonas aeruginosa</i>	Quinolones (alkyl chain)	Biofilm maturation	Alteration of motility	–	Reen <i>et al.</i> (2011)
<i>Streptococcus mutans</i>	<i>Streptococcus salivarius</i>	Exo- β -D-fructosidase	Biofilm maturation	Sucrose digestion	<i>fruA</i>	Ogawa <i>et al.</i> (2011a)
<i>Candida albicans</i>	<i>Pseudomonas aeruginosa</i>	–	Biofilm maturation	Downregulation of biofilm-promoting genes, upregulation of biofilm-inhibiting genes, including YWP1	–	Holcombe <i>et al.</i> (2010)
<i>Porphyromonas gingivalis</i>	<i>Streptococcus crisatus</i>	Arginine deiminase	Biofilm maturation	Downregulation of long fimbria (<i>fimA</i>)	<i>arcA</i>	Wu & Xie (2010)
Broad spectrum	<i>Staphylococcus aureus</i>	Nuclease	Biofilm maturation	Degradation of nucleic acids	<i>Nuc1</i>	Tang <i>et al.</i> (2011)
Broad spectrum	<i>Bacillus licheniformis</i>	DNase	Biofilm maturation and detachment	Nuclease activity, DNA degradation	<i>nucB</i>	Nijland <i>et al.</i> (2010)
Broad spectrum	<i>Bacillus subtilis</i> (potentially broad)	D-Aminoacids	Biofilm detachment	Detachment of amyloid fibers from cell wall	racemases	Kolodkin-Gal <i>et al.</i> (2010), Xu & Liu (2011)
<i>Bordetella bronchiseptica</i>	<i>Pseudomonas aeruginosa</i> PA01	Rhamnolipids	Biofilm detachment	–	<i>rhlAB</i>	Boles <i>et al.</i> (2005)
<i>Streptococcus mutans</i>	<i>Lactobacillus reuteri</i>	–	–	–	–	Soderling <i>et al.</i> (2011)

of bacteria and possibly other microorganisms to form and colonize biofilms (Rodrigues *et al.*, 2006b, c; Valle *et al.*, 2006; Walencka *et al.*, 2008b; Rivardo *et al.*, 2009; Jiang *et al.*, 2011; Rendueles *et al.*, 2011). For instance, the well-known surfactin, which is required for *Bacillus subtilis* swarming, also inhibits biofilm formation of different strains, including *Escherichia coli*, *Proteus mirabilis*, and *Salmonella enterica* (Mireles *et al.*, 2001). Similarly, *Pseudomonas* putisolvins, 12 amino acid lipopeptides linked to a hexanoic lipic chain, are active against other *Pseudomonas*

strains (Kuiper *et al.*, 2004). Uropathogenic extraintestinal *E. coli*, on the other hand, were shown to prevent biofilm formation of a wide range of Gram-positive and Gram-negative bacteria because of the release of group 2 capsule, a high molecular weight polysaccharide encoded by the *kps* locus (Valle *et al.*, 2006; Whitfield, 2006). Group 2 capsule increases surface hydrophilicity and reduces bacterial adhesion by inhibiting cell-surface and cell-to-cell interactions in the developing biofilm (Fig. 2; Valle *et al.*, 2006). Recently, a 546-kDa exopolysaccharide (A101) isolated from a marine

Vibrio was also shown to inhibit initial adhesion of both Gram-negative and Gram-positive bacteria (Fig. 3). In addition, the A101 polysaccharide also affected *P. aeruginosa* cell-to-cell interactions and induced biofilm dispersion of *P. aeruginosa*, but not of *Staphylococcus aureus* (Jiang *et al.*, 2011).

While bacterial adhesion may occasionally occur on bare surfaces, most bacterial adhesion events are likely to take place on surfaces already colonized by other microorganisms. Nonbiocidal tension-active molecules produced by adhering bacteria can prevent entry of incoming bacteria into already formed biofilms. For example, a natural *E. coli* isolate was shown to produce a mannose-rich polysaccharide that impairs *S. aureus* ability to adhere and colonize mature *E. coli* biofilm (Rendueles *et al.*,

2011). In the same study, up to 20% of the screened *E. coli* species produced antibiofilm compounds, suggesting that although colonization resistance could involve other mechanisms, widespread production of antibiofilm polysaccharides could significantly contribute to colonization resistance.

Sabotaging the new neighbors: Inhibition of biofilm maturation

After initial adhesion events, bacteria establish tight surface bonds and connections that enable characteristic biofilm three-dimensional growth and maturation (Fig. 1). This biofilm formation step can be impacted by several nonbiocidal bacterial activities.




Fig. 2. Group 2 capsule alters cell-to-surface and cell-to-cell interactions. (a) Schematic representation of inhibitory cell-to-surface interactions. (b) Biofilm formation of *Escherichia coli* MG1655 F' using untreated glass slides (control), glass slides treated with CFT073 supernatant (group 2 capsule) and glass slides treated with CFT073 $\Delta kpsD$ supernatant devoid of group 2 capsule. (c) Schematic representation of inhibitory cell-to-cell interactions. *Escherichia coli* possesses several extracellular structures that enable bacteria to interact among themselves, such as autotransporters (antigen 43), conjugative pili, curli, and polysaccharides such as cellulose. Expression of these factors generally leads to aggregation and clumping. (d) Autoaggregation assay with MG1655 $\Delta oxyR$ (Ag43) autotransporter adhesin overexpression); cells were diluted to $OD_{600\text{nm}} = 2$ in 3 mL of M63B1 medium (triangles), treated either with CFT073 supernatant (circles) or $\Delta kpsD$ supernatant (squares). Adapted from Valle *et al.* (2006). (e) GFP-tagged MG1655 F' inoculated in a flow cell and monitored by confocal microscopy. CFT073 or inactive supernatants were supplemented after 3 h of culture, and biofilms were grown for 12 h.




Fig. 3. Treatment of anti-biofilm molecules in *P. aeruginosa* and *S. aureus* biofilms. Flow cell images of *P. aeruginosa* FRD1 and *S. aureus* RN6390 without (control) and with 100 mg mL^{-1} A101 polysaccharide. *Pseudomonas aeruginosa* was cultured at 25°C for 2 days and *S. aureus* was grown at 37°C for 24 h. From Jiang *et al.* (2011).

Bonding inhibition: downregulating expression of competitor's adhesins

The studies of the oral ecosystem have provided valuable insight into several mechanisms leading to competitive inhibition of biofilm maturation at the transcriptional level. For instance, surface arginine deiminase ArcA of *Streptococcus cristatus* downregulates expression of *fimA*, which encodes the major subunit of *Porphyromonas gingivalis* long fimbriae and is required for irreversible attachment and further biofilm development (Xie *et al.*, 2000, 2007). A similar study reported that an ArcA homolog of *Streptococcus intermedius* also abolished biofilm formation, but not the growth rate of *P. gingivalis*, by downregulating expression of both short (*mfa1*) and long (*fimA*) fimbriae (Christopher *et al.*, 2010). While the exact mechanism behind this downregulation remains unclear, it has been shown that the regulatory role of ArcA is independent of ArcA deiminase activity (Xie *et al.*, 2007; Wu & Xie, 2010) and requires growth-phase-controlled release of ArcA into the extracellular medium by *S. intermedius* (Christopher *et al.*, 2010).

Matrix exopolysaccharides, besides being essential building blocks of most biofilms and protecting bacteria from desiccation, were recently reported to act as signaling molecules that induce gene expression changes in surrounding bacteria. Formation of biofilms by enterohemorrhagic *E. coli* (EHEC) was, for instance, strongly decreased in the presence of exopolysaccharides extracted from the probiotic bacterium *Lactobacillus acidophilus*. While EHEC growth rates and quorum sensing were not affected, transcription of genes for curli (*crl*, *csgA*, and *csgB*) and chemotaxis (*cheY*) was severely downregulated (Kim *et al.*, 2009). This suggested that *L. acidophilus* polysaccharides could interfere with expression of EHEC surface adhesins. The ability of *L. acidophilus* EPS to inhibit other Gram-positive and Gram-negative biofilms was also demonstrated in *Salmonella enteritidis*, *Salmonella typhimurium*, *Yersinia enterocolitica*, *P. aeruginosa*, and *Listeria monocytogenes* (Kim *et al.*, 2009).

Jamming communication of newcomers

Another hallmark of biofilm physiology is quorum sensing, a density- and dose-dependent communication system that coordinates gene expression at the community level (Bassler & Losick, 2006). While quorum sensing regulates a wide range of functions, controls many virulence traits, and plays an important role in bacterial biofilm formation, it is also involved in the development of mixed species populations (McNab *et al.*, 2003; An *et al.*, 2006). Following increasing interest in identification of molecules interfering with bacterial quorum sensing, it was early shown that bacteria themselves can impair, inhibit, and quench quorum sensing (Ji *et al.*, 1997; Dong *et al.*, 2001). For instance, the *agr* quorum sensing system involved in *S. aureus* virulence and colonization can be subjected to cross-inhibition by closely related strains (Ji *et al.*, 1997). Bacteria can also produce enzymes degrading some quorum sensing molecules, typically acylhomoserine lactones (AHLs), such as AHL lactonase, AHL acylases, and AHL oxidoreductases (Dong *et al.*, 2002; Dong & Zhang, 2005; Czajkowski & Jafra, 2009). Quorum sensing interferences also directly affect bacterial ability to form biofilm, as in the case of *Bacillus cereus* production of AiiA, an AHL lactonase that inhibits *Vibrio cholerae* biofilm formation (Augustine *et al.*, 2010), or bacterial extracts containing phenolic groups and aliphatic amines inhibiting biofilm formation by interfering with *P. aeruginosa* PAO1 quorum sensing (Nithya *et al.*, 2010b; Musthafa *et al.*, 2011).

The oral environment provides other examples of enzymes degrading bacterial communication signals. Two recent studies showed that the outcome of colonization by *Streptococcus mutans*, the primary etiologic agent of human dental caries, relies on successful interactions with other early dental colonizers such as, for instance, *Streptococcus gordonii*. However, *S. gordonii* secretes the serine protease challsin, which inactivates the *S. mutans* competence-stimulating peptide (CSP), a quorum sensing signaling molecule essential for biofilm formation, colonization, and subsequent plaque development (Senadheera

& Cvitkovitch, 2008). In contrast, *Actinomyces naelundii*, another early colonizer of teeth, has weak overall protease activity that does not impair *S. mutans* in colonizing the shared niche, therefore indicating a role of challsin in preventing colonization by other *Streptococcus* spp. (Wang *et al.*, 2011).

Targeting the biofilm scaffold: matrix inhibition

As we have seen above, the biofilm matrix plays a key structural, defensive and sometimes regulatory role (Sutherland, 2001). It maintains bacterial cohesion, acts as a protective barrier and nutrient sink, and enables biofilm maturation (Flemming *et al.*, 2007; Flemming & Wingender, 2010). The biofilm matrix is therefore an ideal target for compromising the ability of other bacteria to establish and form biofilms (Otto, 2008; Jabbouri & Sadovskaya, 2010; Schillaci, 2011).

Degradation of polysaccharide components of the matrix

Major components of the matrix are polysaccharides (Flemming & Wingender, 2010), whose degradation could potentially prevent biofilm formation in mixed species context. Several enzymes degrading matrix polysaccharides have been identified. For instance, *Actinobacillus actinomycetemcomitans*, a predominant oral bacterium, produces dispersin B that degrades poly-*N*-acetylglucosamine (PNAG), a major polysaccharide component of many bacterial extracellular matrices (Kaplan *et al.*, 2003). This β -hexosaminidase, belonging to the glycosyl hydrolase family, is a matrix-degrading enzyme encoded by the *dspB* locus which can effectively interfere with and disperse pre-existing biofilms of *Staphylococcus epidermidis* by degrading its polysaccharide intercellular adhesin, as well as biofilms of other Gram-positive and Gram-negative bacteria (Kaplan *et al.*, 2004). Matrix-degrading enzymes have also been described for other bacteria, although their role in potential intra-biofilm competition is less clearly established, as opposed to self-destruction and biofilm dispersion (see section Forcing neighbors out: biofilm dispersion). For example, *P. aeruginosa* alginate lyase degrades alginate and *Methanosarcina mazei* disaggregatase reduces matrix polymers into trisaccharide units (Xun *et al.*, 1990; Boyd & Chakrabarty, 1994). Nevertheless, we cannot exclude that the primary role of such molecules is to control biofilm formation of producer themselves rather than antagonizing other species (see also section Avoiding neighbors: biofilm self-inhibition).

A recent study has shown that *Streptococcus salivarius*, a commensal bacterium colonizing the oral, tongue, and

throat epithelia, produces a fructosyltransferase and an exo- β -D-fructosidase (FruA) inhibiting matrix formation and hindering further biofilm development of other oral bacteria, including *S. mutans*. The inhibitory activity of FruA depends on sucrose concentration, because FruA is more active with increasing sucrose concentrations in *in vitro* (microtiter plates coated with hydroxyapatite and saliva) and *in vivo* models of *S. salivarius*/*S. mutans* mixed biofilm mimicking oral and teeth conditions (Ogawa *et al.*, 2011).

Degradation of nucleic acid component of the matrix

Nucleases such as DNase and RNase were shown to affect integrity of biofilms by degrading nucleic acid scaffold components of the extracellular matrix (Whitchurch *et al.*, 2002). Some bacteria release DNase into the medium and can inhibit biofilm formation of other DNA-dependent biofilm-forming strains. For example, the marine bacterium *Bacillus licheniformis* produces a broad spectrum DNase encoded by the *nucB* gene and is able to rapidly disperse (in 2 min) competing Gram-negative and Gram-positive biofilms and prevent *de novo* biofilm formation (Nijland *et al.*, 2010). Another recent study showed similar effects of the *S. aureus* nuclease Nuc1 upon the ability to form biofilms of several bacteria, including *P. aeruginosa*, *Actinobacillus pleuropneumoniae*, and *Haemophilus parasuis* (Tang *et al.*, 2011). In addition, there is much evidence that nucleases play a central role in shaping staphylococcal biofilm formation and architecture (Fredheim *et al.*, 2009; Mann *et al.*, 2009).

Degradation of protein components of the matrix

Nonbiocidal antibiofilm molecules can also target matrix-associated proteins. Proteins can either be thoroughly degraded or cut loose from bacterial cell walls by proteases. *Staphylococcus epidermidis*, a commensal bacterium from skin and nose epithelia, inhibits *S. aureus* biofilm formation through production of a serine protease, Esp, which degrades the *S. aureus* matrix without affecting its growth rate (Iwase *et al.*, 2010). Epidemiological studies showed that volunteer nasal cavities carrying Esp-secreting *S. epidermidis* were not colonized by *S. aureus*. Moreover, co-cultures of *S. aureus* with Esp for more than a year did not alter Esp efficiency of biofilm inhibition, indicating that no tolerance or resistance mechanisms arose over time. Interestingly, Esp also stimulates *in vivo* human beta defensin-2, which itself displays low bactericidal activity toward *S. aureus*. Hence, Esp production by *S. epidermidis*

controls *S. aureus* biofilm formation in *in vitro* and *in vivo* contexts through different mechanisms; matrix degradation, inhibition of initial adhesion, and immune system stimulation (Iwase *et al.*, 2010).

Forcing neighbors out: biofilm dispersion

Dispersion is the final step in the life cycle of a biofilm and is considered a regulated process involving cell death, matrix-degrading enzymes, induction of cellular motility and potentially other environmentally triggered mechanisms (Boles *et al.*, 2005; Karatan & Watnick, 2009). Although some of the molecules involved in dispersion have a broad spectrum of activity against biofilms formed by other bacteria, dispersion has mostly been studied in monospecies cultures, and very few data are available on dispersion as a means of competing with other biofilm-forming bacteria in a mixed biofilm context.

The plant pathogen *Xanthomonas campestris* forms mannane-rich biofilms that clump plant vessels. *X. campestris* dissolves its own biofilms via production of a mannane-degrading enzyme, an endo- β -1,4-mannosidase regulated by *cis*-unsaturated fatty acid diffusible signal factors (DSFs; Ryan & Dow, 2011; Wang *et al.*, 2004). Two enzymes have been implicated in synthesis of DSF, RpfB, and RpfF, and a two-component regulatory system, RpfC–RpfG, that senses and transduces signals into the cells (Slater *et al.*, 2000). However, *X. campestris* DSF effects on other bacterial biofilms remain unknown. Following the description of *X. campestris* DSF, several other small fatty acids produced by other bacteria were characterized based on homology with the RpfF–RpfC genes of *X. campestris* implicated in cell-to-cell communication and antibiofilm activity through a signaling cascade involving histidine kinases (RpfC; Ryan & Dow, 2011). For instance, *cis*-2-decenoic acid produced by *P. aeruginosa* disperses *Klebsiella pneumoniae*, *E. coli*, *B. subtilis*, *S. aureus*, and even *Candida* biofilms, as shown by competition experiments (Davies & Marques, 2009). However, not all DSFs share the same mechanism of action or lead to similar phenotypes. For instance, DSF from *Stenotrophomonas maltophilia* does not disperse *P. aeruginosa* biofilms, but rather alters its biofilm architecture and induces formation of filamentous structures (Ryan *et al.*, 2008; Ryan & Dow, 2011). In addition, *N*-butanoyl-homoserine lactone from *Serratia marcescens* mediates its biofilm dispersion (Rice *et al.*, 2005), and *P. aeruginosa* rhamnolipids encoded by the *rhlAB* operon are involved in biofilm structure and dispersion (Boles *et al.*, 2005). Here again, however, there is still no evidence that these signals interfere with other biofilm-forming bacteria.

Another well-studied dispersion signal is nitric oxide (NO) produced by bacteria growing in the deep layers of biofilms under anaerobic conditions. Following microarray results that indicated that NO significantly down-regulated adhesin synthesis in *P. aeruginosa* (Firoved *et al.*, 2004), it was shown that low (nanomolar) concentrations of NO control the ratio of biofilm versus planktonic cells and induce dispersion of various mono- and multispecies biofilms (Barraud *et al.*, 2009). Also in *P. aeruginosa*, NO induces swimming and swarming motility functions, leading to *P. aeruginosa* biofilm dispersion (Barraud *et al.*, 2006). In the presence of low concentrations of NO, the levels of intracellular *c*-di-GMP, a ubiquitous bacterial second messenger generally promoting biofilm formation (Hengge, 2009), were severely reduced because of upregulation of a phosphodiesterase, which degrades *c*-di-GMP (Barraud *et al.*, 2009).

D-amino acids produced by many bacteria at late stages of growth (Lam *et al.*, 2009) including stationary phase and biofilms were recently shown to disperse bacterial biofilms (Kolodkin-Gal *et al.*, 2010; Xu & Liu, 2011). In the specific case of *B. subtilis*, racemases encoded by *racX* and *ylmE* produce D-amino acids such as D-tyrosine, D-leucine, D-tryptophan, and D-methionine which substitute L-isomers in the cell wall and inhibit TasA amyloid fiber anchorage (Kolodkin-Gal *et al.*, 2010; Romero *et al.*, 2011). Because tethering of TasA to the bacterial cell surface is an essential step in matrix-dependent biofilm maturation by *B. subtilis*, D-amino acid accumulation disrupts the *B. subtilis* biofilm. Although this is proposed to be a process by which bacteria can self-disperse their own biofilms, the fact that exogenous addition of D-amino acids also disassembles *S. aureus* and *P. aeruginosa* biofilms (Kolodkin-Gal *et al.*, 2010) suggests that D-amino acid production may also interfere with neighbors in the maturation of mixed biofilms. Different mechanisms of action for D-amino acids have been reported; for instance, D-amino acids inhibit accumulation of proteins in the *S. aureus* matrix and development of microcolonies (Hochbaum *et al.*, 2011), while D-tyrosine significantly reduces synthesis of auto-inducer 2 and extracellular polysaccharides (Xu & Liu, 2011).

Cross-kingdom antibiofilm behaviors

Evidence for nonbiocidal activities leading to limitation of biofilm development also exists across kingdoms (Lowery *et al.*, 2008). The best studied of these mild-mannered antagonistic interactions generally are fungi and bacteria (Hogan & Kolter, 2002; Hughes & Sperandio, 2008). For instance, in the case of *Candida albicans* and *P. aeruginosa*, two microorganisms that co-colonize the lungs of patients with cystic fibrosis or severe burn wounds,

P. aeruginosa was shown to impair biofilm development and maturation of *C. albicans*. A transcriptome analysis of *Candida* genes in the presence of a *Pseudomonas* supernatant revealed downregulation of adhesion and biofilm formation genes and upregulation of *YWPI*, a protein known to inhibit biofilm formation (Holcombe *et al.*, 2010). Another group reported that *P. aeruginosa* can antagonize biofilm formed by other *Candida* species (Bandara *et al.*, 2010). Reciprocally, farnesol, produced by many fungi including *C. albicans*, has been shown to inhibit quinolone synthesis of *P. aeruginosa* and subsequently to downregulate quinolone-controlled genes such as those specifying pyocyanin, which is involved in *P. aeruginosa* virulence (Cugini *et al.*, 2007).

Fungi produce a wide range of secondary metabolites potentially involved in microbial interactions (Mathivanan *et al.*, 2008). Besides well-known antibiotics, fungi such as Ascomycotina produce zaragozic acids, which are competitive inhibitors of squalene synthase (Bergstrom *et al.*, 1993) and inhibit the formation of microdomains in bacterial membranes known as lipid rafts (Lopez & Kolter, 2010). Zaragozic acids have been recently shown to inhibit *B. subtilis* and *S. aureus* biofilms without affecting bacterial viability via inhibition of membrane lipid raft formation, where signaling and transport proteins involved in biofilm formation are clustered (Lopez & Kolter, 2010).

Another well-described cross-kingdom interaction is the use of molecular mimicry by *Delisea pulchra*, an Australian red alga. *D. pulchra* produces halogenated furanones (Givskov *et al.*, 1996), which are similar to AHLs and inhibit quorum sensing of Gram-negative bacteria by reducing the AHL receptor half-life, thus altering AHL-dependent gene expression (Manefield *et al.*, 2002). Similarly, *Flustra foliacea*, a moss animal, produces an alkaloid reported to be an AHL antagonist (Peters *et al.*, 2003).

Many studies explored potential cross-talk between bacteria and their hosts (Hughes & Sperandio, 2008). The host innate response indeed possesses an arsenal of molecules against microbial pathogens, including antibiofilm compounds that efficiently reduce microbial surface colonization (Ardehali *et al.*, 2002, 2003; Hell *et al.*, 2009; Zinger-Yosovich *et al.*, 2010). For instance, PLUNC (palate, lung, nasal epithelium clone) is a protein secreted by epithelia in conducting airways as well as in several fluids including saliva, nasal, and tracheal fluids. This protein displays marked hydrophobicity and significantly reduces surface tension. At physiological concentrations, PLUNC inhibits *P. aeruginosa* biofilms in an *in vitro* model (Gakhar *et al.*, 2010). Similarly, numerous studies have described the antiadhesion role of bloodstream serum and albumin. Serum inhibits biofilm formation and enhances dispersion of *P. aeruginosa* by inducing twitching motility. These effects were demonstrated both *in vitro* and on *in situ* catheters,

and it was suggested that the inhibitory activity is multifactorial rather than relying on a single serum component (Hammond *et al.*, 2008). In addition, human albumin also inhibits strong biofilm-forming *E. coli*, both in direct incubation or as pretreatment on a plastic surface. However, in the latter case, albumin-dependent iron chelation, and therefore growth limitation, may also be involved (Naves *et al.*, 2010). Other strategies, which involve iron as a regulatory element of bacterial lifestyle, can affect initiation of biofilm formation without affecting bacterial growth. For instance, lactoferrin is a protein naturally produced by humans which, at physiological concentrations, does not affect bacterial viability but reduces *P. aeruginosa* biofilms by chelating environmental iron (Singh *et al.*, 2002). Furthermore, lactoferrin was shown to induce twitching motility in *P. aeruginosa* and therefore to favor movement rather than sessile life within a biofilm (Singh, 2004). Motility induced by iron deficiency has been recently shown to be regulated by quorum sensing (Patriquin *et al.*, 2008).

More recently, it was reported that human nonspecific secretory immunoglobulin A (SIgA) was able to inhibit biofilm formation of *V. cholerae* without affecting the viability of the bacteria. *In vivo* studies have shown that IgA^{-/-} mice are heavily colonized by *V. cholerae* compared with the wild type. Further experiments showed that the biofilm-inhibitory active element of SIgA is the mannose-rich secretory domain of SIgA. Consistently, mannose could also inhibit *V. cholerae* biofilm formation in a dose-dependent manner (Murthy *et al.*, 2011).

Biofilm-specific antiadhesion molecules?

Biofilms constitute an original lifestyle in which it has been estimated that up to 10% of the bacterial genome could be differentially regulated, compared to planktonic conditions (Whiteley *et al.*, 2001; Schembri *et al.*, 2003; Beloin *et al.*, 2004; Lazazzera, 2005). A few studies provide evidence that these changes in gene expression lead to production of biofilm-specific metabolites and polymers (Beloin *et al.*, 2004; Matz *et al.*, 2008; Valle *et al.*, 2008; Colvin *et al.*, 2011). Some of these biofilm-associated molecules display antagonist activities against other microorganisms in mixed species contexts. For example, accumulation of amino acid valine in biofilm formed by many Gram-negative bacteria inhibits the growth of several valine-sensitive *E. coli* natural isolates (Valle *et al.*, 2008). Similarly, *B. licheniformis* produces antimicrobial compounds against other *Bacillus* species when cultured as a biofilm, whereas biocidal activity is significantly reduced when grown in shaken cultures (Yan *et al.*, 2003).

While nonbiocidal antibiofilm molecules are not *stricto sensu* biofilm-specific, because traces can still be detected

in planktonic conditions, such molecules appear to be strongly produced within a biofilm (Fig. 4a). For instance, genes involved in the synthesis and regulation of the Ec300p antibiofilm polysaccharide (e.g. *rfaH*) produced by a natural *E. coli* isolate (*E. coli* Ec300) are upregulated in late stationary phase and biofilms (Fig. 4b). Altogether, this leads to increased production of Ec300p within biofilms (Rendueles *et al.*, 2011). A linear polysaccharide (PAM galactan) is copiously produced within biofilms formed by the oral bacterium *Kingella kingae*, whereas yields obtained from batch cultures are significantly lower (Bendaoud *et al.*, 2011). While further studies of genes whose expression is cryptic under planktonic conditions may still uncover the existence of true biofilm-specific molecules (Ghigo, 2003; Korea *et al.*,

2010), high cell densities within biofilms have already revealed molecules which are poorly produced or not detected in batch cultures and which affect population dynamics in mixed bacterial communities (Bendaoud *et al.*, 2011; Rendueles *et al.*, 2011).

Avoiding neighbors: biofilm self-inhibition

Many nonbiocidal antiadhesion molecules described in this review were first identified in monospecies biofilms, and their effects on biofilms formed by other bacteria were often studied only using purified compounds. The ecological role of these molecules has not always been analyzed in mixed biofilms, and their status of antiadhesion weapons interfering with competing neighbors may have been oversold. Indeed, considering that the ultimate strategy for bacteria to avoid interacting with other bacteria could be to inhibit their own ability to adhere to surfaces or to other bacteria in mixed biofilms, biofilm-inhibitory molecules may well serve other purposes. They may be involved in adhesion self-control so as to avoid the cost associated with building a biofilm. Alternatively, avoiding the formation of biofilm may reduce the fitness cost of sheltering spontaneous nonadhering scroungers that invade biofilms and benefit from the community goods without contributing to biofilm formation. Furthermore, far from being involved in intra-biofilm warfare, the net outcome of antiadhesion or dispersion molecules could be an increase in self-dispersion, enabling colonization of other niches or rescue of bacteria trapped in the nutrient- and oxygen-deprived matrix. The synthesis and release of the broad spectrum antibiofilm group 2 capsule by most extra-intestinal *E. coli* is an example in which a nonbiocidal antibiofilm molecule also has an effect upon the producing strain (Valle *et al.*, 2006). While *kps* mutants of uropathogenic *E. coli*, which are unable to synthesize the group 2 capsule, acquire the ability to form thick mature biofilms, wild-type strains are poor biofilm formers, and it is tempting to speculate that their resulting weak ability to mingle with an intestinal biofilm may be correlated with their frequent occurrence in the urogenital tract (Valle *et al.*, 2006).

This therefore raises the question of whether true interference molecules exist. One study reports that nonbiocidal interference molecules are inactive toward the producing strain such as *E. coli* Ec300, which is immune to its antiadhesion polysaccharide, but active against Gram-positive bacteria (Rendueles *et al.*, 2011). Future studies of mixed populations rather than monocultures should contribute to elucidating the ecological role of antibiofilm molecules.




Fig. 4. Antiadhesion polysaccharide produced by *Escherichia coli* Ec300 is produced in higher quantities within biofilms. (a) *Staphylococcus aureus* biofilm inhibition upon the addition of planktonic or biofilm supernatant from *E. coli* Ec300. M63B1, control in which only M63B1 minimal medium was added. (b) Beta-galactosidase activity measurements of a *lacZ* transcriptional fusion in *rfaH*, the transcriptional regulator gene of *E. coli* Ec300 controlling antiadhesion polysaccharide, in exponential phase, late stationary phase (24 h) and biofilm (72 h). Adapted from Rendueles *et al.* (2011) and unpublished data.

Lessons to be learned from bad-neighborliness

Although biofilms are ubiquitous and often beneficial, they are also harmful as industrial biofouling agents and as resilient infectious foyers of chronic infections in patients on medical devices (Costerton *et al.*, 1999; Donlan & Costerton, 2002; Parsek & Singh, 2003). This has led many studies to focus on identifying potential treatment of detrimental biofilms both in industrial and medical settings, notably related to catheter-associated biofilms (Francolini & Donelli, 2010; Donlan, 2011). In addition to new biocides and antimicrobial compounds, several alternative antibiofilm strategies have recently emerged. These approaches range from hydrophilic and nanoparticle coatings to more aggressive strategies such as bacteriophages and biofilm predation agents for grazing on problematic biofilm-forming, for instance, in drinking water facilities (Donlan, 2009; Sockett, 2009; Allaker, 2010).

Microbial interference compounds described in this review interfere with several aspects of adhesion and biofilm formation (Fig. 1) and might also be used for non-biocidal biofilm control strategies (Fig. 5). Much effort has gone into chemical synthesis and screens for molecule-mimicking natural compounds. For instance, bicyclic 2-pyridone derivatives (or pilicides) have been identified in screening for inhibitors of assembly of type 1 pili (Pinkner *et al.*, 2006). They act as competitive inhibitors of chaperone-subunit association, an essential step in pili

translocation to the bacterial surface. Similar molecules targeting other adhesion factors, such as curlicides, have also been reported to severely impair curli-dependent biofilm formation and pathogenesis (Pinkner *et al.*, 2006; Aberg & Almqvist, 2007; Cegelski *et al.*, 2009). Attenuation of virulence by acylated hydrazones of salicylaldehydes via inhibition of type III secretion in different strains of *Yersinia*, *Pseudomonas*, *E. coli*, and *Chlamydiae* has also been demonstrated (Aberg & Almqvist, 2007). Competitive inhibition for specific bacterial adhesion is a related strategy aimed at inhibiting fimbrial lectins using specific saccharidic ligands competing with cell-surface-exposed *bona fide* fimbriae ligands (Korea *et al.*, 2011). For instance, mannose-derived residues show high affinity for FimH and can subsequently inhibit adhesion (Klein *et al.*, 2010; Grabosch *et al.*, 2011). Other strategies pursue inhibition of synthases of second messengers involved in the biofilm formation process, such as diguanylate cyclases responsible for c-di-GMP formation (Antoniani *et al.*, 2010) or quorum sensing signals of multiresistant pathogens such as *S. aureus*, where the *agr* system is targeted by RNAIII-inhibiting peptides and their nonpeptide analog hamamelitannin (Kiran *et al.*, 2008); see Bjarnsholt *et al.* (2011) for review of other antiquorum sensing molecules.

Because initial adhesion is often seen as the first step in microbial pathogenesis (Finlay & Falkow, 1989), there is a strong interest in interference molecules hindering pathogen adhesion to mucosa or to indwelling medical devices as an alternative strategy to antibiotics (Reid *et al.*, 2001). In this context, biosurfactants such as glycolipids and




Fig. 5. Summary of nonbiocidal antibiofilm molecules described in this review and their mode of action.

lipoproteins could play an important role in counteracting pathogen activity, as they exhibit low toxicity and high biodegradability effectiveness at different temperatures and pH (Rodrigues *et al.*, 2006a; Falagas & Makris, 2009; Zeraik & Nitschke, 2010).

Alternatively, instead of using purified antiadhesion compounds, whole (probiotic) commensals could be used for protecting a mammalian host via nonbiocidal competition with pathogens (Reid *et al.*, 2001; Kleerebezem & Vaughan, 2009; Quigley, 2010). Interactions between the commensal flora and incoming pathogens may have a positive effect on host health, as commensals act as physical barriers involved in resistance colonization and prevention of pathogen establishment. It has been shown that mice precolonized with several probiotic *E. coli*, including *E. coli* Nissle, are able to clear and avoid colonization of pathogenic *E. coli* O157:H7. Moreover, this barrier effect is not microbe-specific, as hosts precolonized with commensal *E. coli* strains can also lead to clearance of pathogenic *E. coli* (Leatham *et al.*, 2009). Co-incubation of *S. enterica* with aggregating and surface-blanketing *Lactobacillus kefir* strains significantly decreased *Salmonella*'s capacity to adhere to and invade Caco-2/TC-7 cells (Golowczyc *et al.*, 2007). In addition, *L. kefir* releases an unidentified compound that regulates virulence of *Salmonella*, as it significantly reduces induced microvillus disorganization (Golowczyc *et al.*, 2007). Commensal bacteria of the gut can also inhibit pathogen adhesion through induction of nonbiocidal host factors such as mucin production, which reduces the availability and accessibility of adhesion sites (Mack & Sherman, 1991). Co-incubation of lactobacilli with intestinal epithelial cells resulted in upregulation of MUC3 mucin production and correlated with reduced adhesion of enteropathogenic *E. coli* (Mack *et al.*, 2003).

Despite promises of nonbiocidal antibiofilm approaches (Fig. 5), no antibiofilm products are on the market yet. Although this might be attributed to high cost, low specificity and lack of financial interest on the part of pharmaceutical companies (Romero & Kolter, 2011), we should also consider potential drawbacks of certain antibiofilm approaches. Indeed, mixed communities often correspond to complex equilibria, the alteration of which could lead to drastic changes in population structure and composition, potentially leading to the emergence of opportunistic microorganisms or pathogens previously kept under control. Similarly, while the idea of dispersing mature biofilms formed by or hosting pathogens seems extremely tempting, massive bacterial release upon dispersion can have very serious drawbacks, including systemic infection and massive inflammatory responses, though these remain difficult to predict. Nevertheless, results from double-blind placebo-controlled studies are encouraging (Larsson

et al., 2008; Grandy *et al.*, 2010; Berggren *et al.*, 2011; Choi *et al.*, 2011; Davidson *et al.*, 2011). However, although attractive, these strategies will need to be carefully tested to determine their validity and health benefits.

Concluding remarks

In nature, bacteria interact with and influence each other in complex webs of multicellular behaviors. The studies of these interactions have shed light on the resources used by bacteria to thrive in mixed biofilm communities and have inspired us to design alternatives to antibiotics in the war against pathogenic microorganisms (Rasko & Sperandio, 2010). Targeting surface colonization rather than overall bacterial fitness is emerging as a promising approach, because nonbiocidal modification of pathogenic behavior causes milder evolutionary selective pressure and may therefore lead to the emergence of fewer resistant mutants and fewer toxicity issues. The effectiveness of antibiofilm approaches will be put to test in the coming years. Meanwhile, the hunt for antibiofilm molecules used alone or in combination with antibiotics and vaccines is under active investigation (Goldman *et al.*, 2006; Sanz *et al.*, 2007; Larsson *et al.*, 2008; Rowland *et al.*, 2010; Davidson *et al.*, 2011). It is clear, however, that no single molecule is likely to efficiently control biofilm formation in all types of contexts, underlining the need for a deeper understanding of antagonistic interactions in mixed bacterial populations.

Acknowledgements

We thank C. Beloin, C. Forestier, S. Bernier, M. Mourez, and L. Travier for helpful comments and critical reading of the manuscript. We thank J.B. Kaplan for scientific discussion. We are grateful to Brigitte Arbeille, Claude Lebos, and Gérard Prensier (LBCME, Faculté de Médecine de Tours) for their help in performing electronic microscopy. O.R. was supported by a fellowship from the Network of Excellence EuroPathogenomics; European Community Grant LSHB-CT-2005-512061.

References

- Aberg V & Almqvist F (2007) Pilicides-small molecules targeting bacterial virulence. *Org Biomol Chem* **5**: 1827–1834.
- Allaker RP (2010) The use of nanoparticles to control oral biofilm formation. *J Dent Res* **89**: 1175–1186.
- An D, Danhorn T, Fuqua C & Parsek MR (2006) Quorum sensing and motility mediate interactions between *Pseudomonas aeruginosa* and *Agrobacterium tumefaciens* in biofilm cocultures. *P Natl Acad Sci USA* **103**: 3828–3833.

- Antoniani D, Bocci P, Maciag A, Raffaelli N & Landini P (2010) Monitoring of diguanylate cyclase activity and of cyclic-di-GMP biosynthesis by whole-cell assays suitable for high-throughput screening of biofilm inhibitors. *Appl Microbiol Biotechnol* **85**: 1095–1104.
- Ardehali R, Shi L, Janatova J, Mohammad SF & Burns GL (2002) The effect of apo-transferrin on bacterial adhesion to biomaterials. *Artif Organs* **26**: 512–520.
- Ardehali R, Shi L, Janatova J, Mohammad SF & Burns GL (2003) The inhibitory activity of serum to prevent bacterial adhesion is mainly due to apo-transferrin. *J Biomed Mater Res A* **66**: 21–28.
- Augustine N, Kumar P & Thomas S (2010) Inhibition of *Vibrio cholerae* biofilm by AiiA enzyme produced from *Bacillus* spp. *Arch Microbiol* **192**: 1019–1022.
- Banat IM, Franzetti A, Gandolfi I, Bestetti G, Martinotti MG, Fracchia L, Smyth TJ & Marchant R (2010) Microbial biosurfactants production, applications and future potential. *Appl Microbiol Biotechnol* **87**: 427–444.
- Bandara HM, Yau JY, Watt RM, Jin LJ & Samaranyake LP (2010) *Pseudomonas aeruginosa* inhibits *in-vitro* *Candida* biofilm development. *BMC Microbiol* **10**: 125.
- Barraud N, Hassett DJ, Hwang SH, Rice SA, Kjelleberg S & Webb JS (2006) Involvement of nitric oxide in biofilm dispersal of *Pseudomonas aeruginosa*. *J Bacteriol* **188**: 7344–7353.
- Barraud N, Schleheck D, Klebensberger J, Webb JS, Hassett DJ, Rice SA & Kjelleberg S (2009) Nitric oxide signaling in *Pseudomonas aeruginosa* biofilms mediates phosphodiesterase activity, decreased cyclic di-GMP levels, and enhanced dispersal. *J Bacteriol* **191**: 7333–7342.
- Bassler B & Losick R (2006) Bacterially speaking. *Cell* **125**: 237–246.
- Beloin C, Valle J, Latour-Lambert P, Faure P, Kzreminski M, Balestrino D, Haagensen JA, Molin S, Prensier G, Arbeille B & Ghigo JM (2004) Global impact of mature biofilm lifestyle on *Escherichia coli* K-12 gene expression. *Mol Microbiol* **51**: 659–674.
- Bendaoud M, Vinogradov E, Balashova NV, Kadouri DE, Kachlany SC & Kaplan JB (2011) Broad spectrum biofilm inhibition by *Kingella kingae* exopolysaccharide. *J Bacteriol* **193**: 3879–3886.
- Berggren A, Lazou Ahrén I, Larsson N & Önning G (2011) Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections. *Eur J Nutr* **50**: 203–210.
- Bergstrom JD, Kurtz MM, Rew DJ, Amend AM, Karkas JD, Bostedor RG, Bansal VS, Dufresne C, VanMiddlesworth FL, Hensens OD *et al.* (1993) Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. *P Natl Acad Sci USA* **90**: 80–84.
- Bjarnsholt T, Tolker-Nielsen T & Givskov M (2011) Interfering with “Bacterial Gossip”. *Biofilm Highlights* (Flemming H-C, ed), pp. 163–188. Springer-Verlag, Berlin.
- Boles BR, Thoendel M & Singh PK (2005) Rhamnolipids mediate detachment of *Pseudomonas aeruginosa* from biofilms. *Mol Microbiol* **57**: 1210–1223.
- Boyd A & Chakrabarty AM (1994) Role of alginate lyase in cell detachment of *Pseudomonas aeruginosa*. *Appl Environ Microbiol* **60**: 2355–2359.
- Cegelski L, Pinkner JS, Hammer ND *et al.* (2009) Small-molecule inhibitors target *Escherichia coli* amyloid biogenesis and biofilm formation. *Nat Chem Biol* **5**: 913–919.
- Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS & Myung SJ (2011) A randomized, double-blind, placebo-controlled multicenter trial of *Saccharomyces boulardii* in irritable bowel syndrome: effect on quality of life. *J Clin Gastroenterol* **45**: 679–683.
- Christopher AB, Arndt A, Cugini C & Davey ME (2010) A streptococcal effector protein that inhibits *Porphyromonas gingivalis* biofilm development. *Microbiology (Reading, Engl)* **156**: 3469–3477.
- Colvin KM, Gordon VD, Murakami K, Borlee BR, Wozniak DJ, Wong GC & Parsek MR (2011) The Pel polysaccharide can serve a structural and protective role in the biofilm matrix of *Pseudomonas aeruginosa*. *PLoS Pathog* **7**: e1001264.
- Costerton JW, Cheng KJ, Geesey GG, Ladd TI, Nickel JC, Dasgupta M & Marrie TJ (1987) Bacterial biofilms in nature and disease. *Annu Rev Microbiol* **41**: 435–464.
- Costerton JW, Stewart PS & Greenberg EP (1999) Bacterial biofilms: a common cause of persistent infections. *Science* **284**: 1318–1322.
- Cugini C, Calfee MW, Farrow JM, Morales DK, Pesci EC & Hogan DA (2007) Farnesol, a common sesquiterpene, inhibits PQS production in *Pseudomonas aeruginosa*. *Mol Microbiol* **65**: 896–906.
- Czajkowski R & Jafra S (2009) Quenching of acyl-homoserine lactone-dependent quorum sensing by enzymatic disruption of signal molecules. *Acta Biochim Pol* **56**: 1–16.
- Davidson LE, Fiorino AM, Snyderman DR & Hibberd PL (2011) *Lactobacillus* GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. *Eur J Clin Nutr* **65**: 501–507.
- Davies DG & Marques CN (2009) A fatty acid messenger is responsible for inducing dispersion in microbial biofilms. *J Bacteriol* **191**: 1393–1403.
- Dong YH & Zhang L (2005) Quorum sensing and quorum-quenching enzymes. *J Microbiol* **43 Spec No**: 101–109.
- Dong YH, Wang LH, Xu JL, Zhang HB, Zhang XF & Zhang LH (2001) Quenching quorum-sensing-dependent bacterial infection by an N-acyl homoserine lactonase. *Nature* **411**: 813–817.
- Dong YH, Gusti AR, Zhang Q, Xu JL & Zhang LH (2002) Identification of quorum-quenching N-acyl homoserine lactonases from *Bacillus* species. *Appl Environ Microbiol* **68**: 1754–1759.
- Donlan RM (2009) Preventing biofilms of clinically relevant organisms using bacteriophage. *Trends Microbiol* **17**: 66–72.

- Donlan RM (2011) Biofilm elimination on intravascular catheters: important considerations for the infectious disease practitioner. *Clin Infect Dis* **52**: 1038–1045.
- Donlan RM & Costerton JW (2002) Biofilms: survival mechanisms of clinically relevant microorganisms. *Clin Microbiol Rev* **15**: 167–193.
- Dubey GP & Ben-Yehuda S (2011) Intercellular nanotubes mediate bacterial communication. *Cell* **144**: 590–600.
- Dunne WM (2002) Bacterial adhesion: seen any good biofilms lately? *Clin Microbiol Rev* **15**: 155–166.
- Dusane DH, Pawar VS, Nanchaiah YV, Venugopalan VP, Kumar AR & Zinjarde SS (2011) Anti-biofilm potential of a glycolipid surfactant produced by a tropical marine strain of *Serratia marcescens*. *Biofouling* **27**: 645–654.
- Falagas ME & Makris GC (2009) Probiotic bacteria and biosurfactants for nosocomial infection control: a hypothesis. *J Hosp Infect* **71**: 301–306.
- Fernandez-Pinar R, Camara M, Dubern JF, Ramos JL & Espinosa-Urgel M (2011) The *Pseudomonas aeruginosa* quinolone quorum sensing signal alters the multicellular behaviour of *Pseudomonas putida* KT2440. *Res Microbiol* **162**: 773–781.
- Finlay BB & Falkow S (1989) Common themes in microbial pathogenesis. *Microbiol Rev* **53**: 210–230.
- Firoved AM, Wood SR, Ornatowski W, Deretic V & Timmins GS (2004) Microarray analysis and functional characterization of the nitrosative stress response in nonmucoid and mucoid *Pseudomonas aeruginosa*. *J Bacteriol* **186**: 4046–4050.
- Flemming H & Wingender J (2010) The biofilm matrix. *Nat Rev Microbiol* **8**: 623–633.
- Flemming HC, Neu TR & Wozniak DJ (2007) The EPS matrix: the “house of biofilm cells”. *J Bacteriol* **189**: 7945–7947.
- Francolini I & Donelli G (2010) Prevention and control of biofilm-based medical-device-related infections. *FEMS Immunol Med Microbiol* **59**: 227–238.
- Fredheim EG, Klingenberg C, Rohde H, Frankenberger S, Gaustad P, Flaegstad T & Sollid JE (2009) Biofilm formation by *Staphylococcus haemolyticus*. *J Clin Microbiol* **47**: 1172–1180.
- Gakhar L, Bartlett JA, Penterman J, Mizrahi D, Singh PK, Mallampalli RK, Ramaswamy S & McCray PB (2010) PLUNC is a novel airway surfactant protein with anti-biofilm activity. *PLoS ONE* **5**: e9098.
- Ghigo J-M (2003) Are there biofilm-specific physiological pathways beyond a reasonable doubt? *Res Microbiol* **154**: 1–8.
- Goldman CG, Barrado DA, Balcarce N *et al.* (2006) Effect of a probiotic food as an adjuvant to triple therapy for eradication of *Helicobacter pylori* infection in children. *Nutrition* **22**: 984–988.
- Golowcyc MA, Mobili P, Garrote GL, Abraham AG & De Antoni GL (2007) Protective action of *Lactobacillus kefir* carrying S-layer protein against *Salmonella enterica* serovar *Enteritidis*. *Int J Food Microbiol* **118**: 264–273.
- Grabosch C, Hartmann M, Schmidt-Lassen J & Lindhorst TK (2011) Squaric acid monoamide mannosides as ligands for the bacterial lectin FimH: covalent inhibition or not? *Chembiochem* **12**: 1066–1074.
- Grandy G, Medina M, Soria R, Terán CG & Araya M (2010) Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children. *BMC Infect Dis* **10**: 253.
- Hall-Stoodley L, Costerton JW & Stoodley P (2004) Bacterial biofilms: from the natural environment to infectious diseases. *Nat Rev Microbiol* **2**: 95–108.
- Hammond A, Dertien J, Colmer-Hamood JA, Griswold JA & Hamood AN (2008) Serum inhibits *P. aeruginosa* biofilm formation on plastic surfaces and intravenous catheters. *J Surg Res* **159**: 735–746.
- Hell E, Giske CG, Nelson A, Romling U & Marchini G (2009) Human cathelicidin peptide LL37 inhibits both attachment capability and biofilm formation of *Staphylococcus epidermidis*. *Lett Appl Microbiol* **50**: 211–215.
- Henge R (2009) Principles of c-di-GMP signalling in bacteria. *Nat Rev Microbiol* **7**: 263–273.
- Hibbing ME, Fuqua C, Parsek MR & Peterson SB (2010) Bacterial competition: surviving and thriving in the microbial jungle. *Nat Rev Microbiol* **8**: 15–25.
- Hochbaum AI, Kolodkin-Gal I, Foulston L, Kolter R, Aizenberg J & Losick R (2011) Inhibitory effects of D-amino acids on *Staphylococcus aureus* biofilm development. *J Bacteriol* **193**: 5616–5622.
- Hogan DA & Kolter R (2002) *Pseudomonas-Candida* interactions: an ecological role for virulence factors. *Science* **296**: 2229–2232.
- Holcombe LJ, McAlester G, Munro CA, Enjalbert B, Brown AJ, Gow NA, Ding C, Butler G, O’Gara F & Morrissey JP (2010) *Pseudomonas aeruginosa* secreted factors impair biofilm development in *Candida albicans*. *Microbiology* **156**: 1476–1486.
- Hughes DT & Sperandio V (2008) Inter-kingdom signalling: communication between bacteria and their hosts. *Nat Rev Microbiol* **6**: 111–120.
- Iwase T, Uehara Y, Shinji H, Tajima A, Seo H, Takada K, Agata T & Mizunoe Y (2010) *Staphylococcus epidermidis* Esp inhibits *Staphylococcus aureus* biofilm formation and nasal colonization. *Nature* **465**: 346–349.
- Jabbouri S & Sadovskaya I (2010) Characteristics of the biofilm matrix and its role as a possible target for the detection and eradication of *Staphylococcus epidermidis* associated with medical implant infections. *FEMS Immunol Med Microbiol* **59**: 280–291.
- James G, Beaudette L & Costerton JW (1995) Interspecies bacterial interactions in biofilms. *J Ind Microbiol Biotechnol* **15**: 257–262.
- Ji G, Beavis R & Novick RP (1997) Bacterial interference caused by autoinducing peptide variants. *Science* **276**: 2027–2030.
- Jiang P, Li J, Han F, Duan G, Lu X, Gu Y & Yu W (2011) Antibiofilm activity of an exopolysaccharide from marine bacterium *Vibrio* sp. QY101. *PLoS ONE* **6**: e18514.

- Kanmani P, Satish kumar R, Yuvaraj N, Paari KA, Pattukumar V & Arul V (2011) Production and purification of a novel exopolysaccharide from lactic acid bacterium *Streptococcus phocae* PI80 and its functional characteristics activity *in vitro*. *Bioresour Technol* **102**: 4827–4833.
- Kaplan JB, Ragunath C, Ramasubbu N & Fine DH (2003) Detachment of *Actinobacillus actinomycetemcomitans* biofilm cells by an endogenous beta-hexosaminidase activity. *J Bacteriol* **185**: 4693–4698.
- Kaplan JB, Ragunath C, Velliyagounder K, Fine DH & Ramasubbu N (2004) Enzymatic detachment of *Staphylococcus epidermidis* biofilms. *Antimicrob Agents Chemother* **48**: 2633–2636.
- Karatan E & Watnick P (2009) Signals, regulatory networks, and materials that build and break bacterial biofilms. *Microbiol Mol Biol Rev* **73**: 310–347.
- Kim Y, Oh S & Kim SH (2009) Released exopolysaccharide (r-EPS) produced from probiotic bacteria reduce biofilm formation of enterohemorrhagic *Escherichia coli* O157:H7. *Biochem Biophys Res Commun* **379**: 324–329.
- Kiran MD, Giacometti A, Cirioni O & Balaban N (2008) Suppression of biofilm related, device-associated infections by staphylococcal quorum sensing inhibitors. *Int J Artif Organs* **31**: 761–770.
- Kleerebezem M & Vaughan EE (2009) Probiotic and gut lactobacilli and bifidobacteria: molecular approaches to study diversity and activity. *Annu Rev Microbiol* **63**: 269–290.
- Klein T, Abgottspon D, Wittwer M *et al.* (2010) FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to *in vitro* and *in vivo* evaluation. *J Med Chem* **53**: 8627–8641.
- Klein GL, Soum-Soutera E, Guede Z, Bazire A, Compere C & Dufour A (2011) The anti-biofilm activity secreted by a marine *Pseudoalteromonas* strain. *Biofouling* **27**: 931–940.
- Kline KA, Falker S, Dahlberg S, Normark S & Henriques-Normark B (2009) Bacterial adhesins in host-microbe interactions. *Cell Host Microbe* **5**: 580–592.
- Kolodkin-Gal I, Romero D, Cao S, Clardy J, Kolter R & Losick R (2010) D-amino acids trigger biofilm disassembly. *Science* **328**: 627–629.
- Korea CG, Badouraly R, Prevost MC, Ghigo JM & Beloin C (2010) *Escherichia coli* K-12 possesses multiple cryptic but functional chaperone-usher fimbriae with distinct surface specificities. *Environ Microbiol* **12**: 1957–1977.
- Korea CG, Ghigo JM & Beloin C (2011) The sweet connection: solving the riddle of multiple sugar-binding fimbrial adhesins in *Escherichia coli*: multiple *E. coli* fimbriae form a versatile arsenal of sugar-binding lectins potentially involved in surface-colonisation and tissue tropism. *Bioessays* **33**: 300–311.
- Kuiper I, Legendijk EL, Pickford R, Derrick JP, Lamers GE, Thomas-Oates JE, Lugtenberg BJ & Bloemberg GV (2004) Characterization of two *Pseudomonas putida* lipopeptide biosurfactants, putisolvin I and II, which inhibit biofilm formation and break down existing biofilms. *Mol Microbiol* **51**: 97–113.
- Kumada M, Motegi M, Nakao R, Yonezawa H, Yamamura H, Tagami J & Senpuku H (2009) Inhibiting effects of *Enterococcus faecium* non-biofilm strain on *Streptococcus mutans* biofilm formation. *J Microbiol Immunol Infect* **42**: 188–196.
- Lam H, Oh DC, Cava F, Takacs CN, Clardy J, de Pedro MA & Waldor MK (2009) D-amino acids govern stationary phase cell wall remodeling in bacteria. *Science* **325**: 1552–1555.
- Larsson PG, Stray-Pedersen B, Rytting KR & Larsen S (2008) Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. *BMC Womens Health* **15**: 3.
- Lazizzera BA (2005) Lessons from DNA microarray analysis: the gene expression profile of biofilms. *Curr Opin Microbiol* **8**: 222–227.
- Leatham MP, Banerjee S, Autieri SM, Mercado-Lubo R, Conway T & Cohen PS (2009) Precolonized human commensal *Escherichia coli* strains serve as a barrier to *E. coli* O157:H7 growth in the streptomycin-treated mouse intestine. *Infect Immun* **77**: 2876–2886.
- Lopez D & Kolter R (2010) Functional microdomains in bacterial membranes. *Genes Dev* **24**: 1893–1902.
- Lowery CA, Dickerson TJ & Janda KD (2008) Interspecies and interkingdom communication mediated by bacterial quorum sensing. *Chem Soc Rev* **37**: 1337–1346.
- Mack DR & Sherman PM (1991) Mucin isolated from rabbit colon inhibits *in vitro* binding of *Escherichia coli* RDEC-1. *Infect Immun* **59**: 1015–1023.
- Mack DR, Ahrne S, Hyde L, Wei S & Hollingsworth MA (2003) Extracellular MUC3 mucin secretion follows adherence of *Lactobacillus* strains to intestinal epithelial cells *in vitro*. *Gut* **52**: 827–833.
- Manefield M, Rasmussen TB, Henzter M, Andersen JB, Steinberg P, Kjelleberg S & Givskov M (2002) Halogenated furanones inhibit quorum sensing through accelerated LuxR turnover. *Microbiology* **148**: 1119–1127.
- Mann EE, Rice KC, Boles BR, Endres JL, Ranjit D, Chandramohan L, Tsang LH, Smeltzer MS, Horswill AR & Bayles KW (2009) Modulation of eDNA release and degradation affects *Staphylococcus aureus* biofilm maturation. *PLoS ONE* **4**: e5822.
- Mathivanan N, Prabavathy VR & Vijayanandraj VR (2008) The effect of fungal secondary metabolites on bacterial and fungal pathogens. *Secondary Metabolites in Soil Ecology, Soil Biology*, Volume 14, III, (Karlovsky P, ed.), pp. 129–140.
- Matz C, Webb JS, Schupp PJ, Phang SY, Penesyan A, Egan S, Steinberg P & Kjelleberg S (2008) Marine biofilm bacteria evade eukaryotic predation by targeted chemical defense. *PLoS ONE* **3**: e2744.
- McNab R, Ford SK, El-Sabaeny A, Barbieri B, Cook GS & Lamont RJ (2003) LuxS-based signaling in *Streptococcus gordonii*: autoinducer 2 controls carbohydrate metabolism and biofilm formation with *Porphyromonas gingivalis*. *J Bacteriol* **185**: 274–284.

- Mireles JR 2nd, Toguchi A & Harshey RM (2001) *Salmonella enterica* serovar typhimurium swarming mutants with altered biofilm-forming abilities: surfactin inhibits biofilm formation. *J Bacteriol* **183**: 5848–5854.
- Moons P, Michiels C & Aertsen A (2009) Bacterial interactions in biofilms. *Crit Rev Microbiol* **35**: 157–168.
- Mowat E, Rajendran R, Williams C, McCulloch E, Jones B, Lang S & Ramage G (2010) *Pseudomonas aeruginosa* and their small diffusible extracellular molecules inhibit *Aspergillus fumigatus* biofilm formation. *FEMS Microbiol Lett* **313**: 96–102.
- Murthy AK, Chaganty BK, Troutman T, Guentzel MN, Yu JJ, Ali SK, Lauriano CM, Chambers JP, Klose KE & Arulanandam BP (2011) Mannose-containing oligosaccharides of non-specific human secretory immunoglobulin A mediate inhibition of *Vibrio cholerae* biofilm formation. *PLoS ONE* **6**: e16847.
- Musthafa KS, Saroja V, Pandian SK & Ravi AV (2011) Antipathogenic potential of marine *Bacillus* sp. SS4 on N-acyl-homoserine-lactone-mediated virulence factors production in *Pseudomonas aeruginosa* (PAO1). *J Biosci* **36**: 55–67.
- Naves P, del Prado G, Huelves L, Rodriguez-Cerrato V, Ruiz V, Ponte MC & Soriano F (2010) Effects of human serum albumin, ibuprofen and N-acetyl-L-cysteine against biofilm formation by pathogenic *Escherichia coli* strains. *J Hosp Infect* **76**: 165–170.
- Neu TR (1996) Significance of bacterial surface-active compounds in interaction of bacteria with interfaces. *Microbiol Rev* **60**: 151–166.
- Nijland R, Hall MJ & Burgess JG (2010) Dispersal of biofilms by secreted, matrix degrading, bacterial DNase. *PLoS ONE* **5**: e15668.
- Nithya C, Aravindraja C & Pandian SK (2010a) *Bacillus pumilus* of Palk Bay origin inhibits quorum-sensing-mediated virulence factors in Gram-negative bacteria. *Res Microbiol* **161**: 293–304.
- Nithya C, Begum MF & Pandian SK (2010b) Marine bacterial isolates inhibit biofilm formation and disrupt mature biofilms of *Pseudomonas aeruginosa* PAO1. *Appl Microbiol Biotechnol* **88**: 341–358.
- Nithya C, Devi MG & Karutha Pandian S (2011) A novel compound from the marine bacterium *Bacillus pumilus* S6-15 inhibits biofilm formation in Gram-positive and Gram-negative species. *Biofouling* **27**: 519–528.
- Nithyanand P, Thenmozhi R, Rathna J & Pandian SK (2010) Inhibition of *Streptococcus pyogenes* biofilm formation by coral-associated actinomycetes. *Current Microbiology* **60**: 454–460.
- Ogawa A, Furukawa S, Fujita S *et al.* (2011) Inhibition of *Streptococcus mutans* biofilm formation by *Streptococcus salivarius* FruA. *Appl Environ Microbiol* **77**: 1572–1580.
- Orgaz B, Kives J, Pedregosa AM, Monistrol IF, Laborda F & SanJos CÉ (2006) Bacterial biofilm removal using fungal enzymes. *Enzyme Microb Technol* **40**: 51–56.
- Otto M (2008) Staphylococcal biofilms. *Curr Top Microbiol Immunol* **322**: 207–228.
- Parsek MR & Singh PK (2003) Bacterial biofilms: an emerging link to disease pathogenesis. *Annu Rev Microbiol* **57**: 677–701.
- Patriquin GM, Banin E, Gilmour C, Tuchman R, Greenberg EP & Poole K (2008) Influence of quorum sensing and iron on twitching motility and biofilm formation in *Pseudomonas aeruginosa*. *J Bacteriol* **190**: 662–671.
- Peters L, Konig GM, Wright AD, Pukall R, Stackebrandt E, Eberl L & Riedel K (2003) Secondary metabolites of *Flustra foliacea* and their influence on bacteria. *Appl Environ Microbiol* **69**: 3469–3475.
- Pinkner JS, Remaut H, Buelens F *et al.* (2006) Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. *P Natl Acad Sci USA* **103**: 17897–17902.
- Qin Z, Yang L, Qu D, Molin S & Tolker-Nielsen T (2009) *Pseudomonas aeruginosa* extracellular products inhibit staphylococcal growth, and disrupt established biofilms produced by *Staphylococcus epidermidis*. *Microbiology* **155**: 2148–2156.
- Quigley EM (2010) Prebiotics and probiotics; modifying and mining the microbiota. *Pharmacol Res* **61**: 213–218.
- Rasko DA & Sperandio V (2010) Anti-virulence strategies to combat bacteria-mediated disease. *Nat Rev Drug Discov* **9**: 117–128.
- Reen FJ, Mooij MJ, Holcombe LJ, McSweeney CM, McGlacken GP, Morrissey JP & O’Gara F (2011) The *Pseudomonas* quinolone signal (PQS), and its precursor HHQ, modulate interspecies and interkingdom behaviour. *FEMS Microbiol Ecol* **77**: 413–428.
- Reid G, Howard J & Gan BS (2001) Can bacterial interference prevent infection? *Trends Microbiol* **9**: 424–428.
- Rendueles O, Travier L, Latour-Lambert P, Fontaine T, Magnus J, Denamur E & Ghigo JM (2011) Screening of *Escherichia coli* species biodiversity reveals new biofilm-associated antiadhesion polysaccharides. *MBio* **2**: e00043–11.
- Rice SA, Koh KS, Queck SY, Labbate M, Lam KW & Kjelleberg S (2005) Biofilm formation and sloughing in *Serratia marcescens* are controlled by quorum sensing and nutrient cues. *J Bacteriol* **187**: 3477–3485.
- Rivardo F, Turner RJ, Allegrone G, Ceri H & Martinotti MG (2009) Anti-adhesion activity of two biosurfactants produced by *Bacillus* spp. prevents biofilm formation of human bacterial pathogens. *Appl Microbiol Biotechnol* **83**: 541–553.
- Rodrigues L, Banat IM, Teixeira J & Oliveira R (2006a) Biosurfactants: potential applications in medicine. *J Antimicrob Chemother* **57**: 609–618.
- Rodrigues L, van der Mei H, Banat IM, Teixeira J & Oliveira R (2006b) Inhibition of microbial adhesion to silicone rubber treated with biosurfactant from *Streptococcus thermophilus* A. *FEMS Immunol Med Microbiol* **46**: 107–112.
- Rodrigues LR, Teixeira JA, van der Mei HC & Oliveira R (2006c) Isolation and partial characterization of a biosurfactant produced by *Streptococcus thermophilus* A. *Colloids Surf B Biointerfaces* **53**: 105–112.
- Romero D & Kolter R (2011) Will biofilm disassembly agents make it to market? *Trends Microbiol* **19**: 304–306.

- Romero D, Vlamakis H, Losick R & Kolter R (2011) An accessory protein required for anchoring and assembly of amyloid fibres in *B. subtilis* biofilms. *Mol Microbiol* **80**: 1155–1168.
- Rowland I, Capurso L, Collins K, Cummings J, Delzenne N, Goulet O, Guarner F, Marteau P & Meier R (2010) Current level of consensus on probiotic science—report of an expert meeting—London, 23 November 2009. *Gut microbes* **1**: 436–439.
- Ryan RP & Dow JM (2011) Communication with a growing family: diffusible signal factor (DSF) signaling in bacteria. *Trends Microbiol* **19**: 145–152.
- Ryan RP, Fouhy Y, Garcia BF, Watt SA, Niehaus K, Yang L, Tolker-Nielsen T & Dow JM (2008) Interspecies signalling via the *Stenotrophomonas maltophilia* diffusible signal factor influences biofilm formation and polymyxin tolerance in *Pseudomonas aeruginosa*. *Mol Microbiol* **68**: 75–86.
- Sanz Y, Nadal I & Sanchez E (2007) Probiotics as drugs against human gastrointestinal infections. *Recent Pat Antiinfect Drug Discov* **2**: 148–156.
- Sayem SM, Manzo E, Ciavatta L, Tramice A, Cordone A, Zanfardino A, De Felice M & Varcamonti M (2011) Antibiofilm activity of an exopolysaccharide from a sponge-associated strain of *Bacillus licheniformis*. *Microb Cell Fact* **10**: 74.
- Schembri MA, Kjaergaard K & Klemm P (2003) Global gene expression in *Escherichia coli* biofilms. *Mol Microbiol* **48**: 253–267.
- Schillaci D (2011) Staphylococcal biofilms: challenges in the discovery of novel anti-infective agents. *J Microbial Biochem Technol* **3**: iv–vi.
- Senadheera D & Cvitkovich DG (2008) Quorum sensing and biofilm formation by *Streptococcus mutans*. *Adv Exp Med Biol* **631**: 178–188.
- Singh PK (2004) Iron sequestration by human lactoferrin stimulates *P. aeruginosa* surface motility and blocks biofilm formation. *Biomaterials* **17**: 267–270.
- Singh PK, Parsek MR, Greenberg EP & Welsh MJ (2002) A component of innate immunity prevents bacterial biofilm development. *Nature* **417**: 552–555.
- Slater H, Alvarez-Morales A, Barber CE, Daniels MJ & Dow JM (2000) A two-component system involving an HD-GYP domain protein links cell-cell signalling to pathogenicity gene expression in *Xanthomonas campestris*. *Mol Microbiol* **38**: 986–1003.
- Sokkett RE (2009) Predatory lifestyle of *Bdellovibrio bacteriovorus*. *Annu Rev Microbiol* **63**: 523–539.
- Soderling EM, Marttinen AM & Haukioja AL (2011) Probiotic lactobacilli interfere with *Streptococcus mutans* biofilm formation *in vitro*. *Current Microbiology* **62**: 618–622.
- Sutherland I (2001) Biofilm exopolysaccharides: a strong and sticky framework. *Microbiology* **147**: 3–9.
- Tamura S, Yonezawa H, Motegi M, Nakao R, Yoneda S, Watanabe H, Yamazaki T & Senpuku H (2009) Inhibiting effects of *Streptococcus salivarius* on competence-stimulating peptide-dependent biofilm formation by *Streptococcus mutans*. *Oral Microbiol Immunol* **24**: 152–161.
- Tang J, Kang M, Chen H, Shi X, Zhou R, Chen J & Du Y (2011) The staphylococcal nuclease prevents biofilm formation in *Staphylococcus aureus* and other biofilm-forming bacteria. *Sci China Life Sci* **54**: 863–869.
- Thenmozhi R, Nithyanand P, Rathna J & Pandian SK (2009) Antibiofilm activity of coral-associated bacteria against different clinical M serotypes of *Streptococcus pyogenes*. *FEMS Immunol Med Microbiol* **57**: 284–294.
- Valle J, Da Re S, Henry N, Fontaine T, Balestrino D, Latour-Lambert P & Ghigo J (2006) Broad-spectrum biofilm inhibition by a secreted bacterial polysaccharide. *P Natl Acad Sci USA* **103**: 12558–12563.
- Valle J, Da Re S, Schmid S, Skurnik D, D'Ari R & Ghigo J (2008) The amino acid valine is secreted in continuous-flow bacterial biofilms. *J Bacteriol* **190**: 264–274.
- Velraeds MM, van der Mei HC, Reid G & Busscher HJ (1996) Inhibition of initial adhesion of uropathogenic *Enterococcus faecalis* by biosurfactants from *Lactobacillus* isolates. *Appl Environ Microbiol* **62**: 1958–1963.
- Walencka E, Rozalska S, Sadowska B & Rozalska B (2008a) The influence of *Lactobacillus acidophilus*-derived surfactants on staphylococcal adhesion and biofilm formation. *Folia Microbiol (Praha)* **53**: 61–66.
- Walencka E, Sadowska B, Wieckowska-Szakiel M & Rozalska B (2008b) [Activity of indolicidin, alone or together with oxacillin, against *Staphylococcus aureus* and *S. epidermidis*]. *Med Dosw Mikrobiol* **60**: 191–196.
- Wang LH, He Y, Gao Y *et al.* (2004) A bacterial cell-cell communication signal with cross-kingdom structural analogues. *Mol Microbiol* **51**: 903–912.
- Wang BY, Deutch A, Hong J & Kuramitsu HK (2011) Proteases of an early colonizer can hinder *Streptococcus mutans* colonization *in vitro*. *J Dent Res* **90**: 501–505.
- Whitchurch CB, Tolker-Nielsen T & Ragas PC (2002) Extracellular DNA required for bacterial biofilm formation. *Science* **295**: 1487.
- Whiteley M, Bangera MG, Bumgarner RE, Parsek MR, Teitzel GM, Lory S & Greenberg EP (2001) Gene expression in *Pseudomonas aeruginosa* biofilms. *Nature* **413**: 860–864.
- Whitfield C (2006) Biosynthesis and assembly of capsular polysaccharides in *Escherichia coli*. *Annu Rev Biochem* **75**: 39–68.
- Wu J & Xie H (2010) Role of arginine deiminase of *Streptococcus cristatus* in *Porphyromonas gingivalis* colonization. *Antimicrob Agents Chemother* **54**: 4694–4698.
- Xie H, Cook GS, Costerton JW, Bruce G, Rose TM & Lamont RJ (2000) Intergeneric communication in dental plaque biofilms. *J Bacteriol* **182**: 7067–7069.
- Xie H, Lin X, Wang BY, Wu J & Lamont RJ (2007) Identification of a signalling molecule involved in bacterial intergeneric communication. *Microbiology* **153**: 3228–3234.
- Xu H & Liu Y (2011) D-Amino acid mitigated membrane biofouling and promoted biofilm detachment. *Anglais* **376**: 9.
- Xun LY, Mah RA & Boone DR (1990) Isolation and characterization of disaggregatase from *Methanosarcina mazei* LYC. *Appl Environ Microbiol* **56**: 3693–3698.

- Yan L, Boyd KG, Adams DR & Burgess JG (2003) Biofilm-specific cross-species induction of antimicrobial compounds in bacilli. *Appl Environ Microbiol* **69**: 3719–3727.
- You J, Xue X, Cao L, Lu X, Wang J, Zhang L & Zhou S (2007) Inhibition of *Vibrio* biofilm formation by a marine actinomycete strain A66. *Appl Microbiol Biotechnol* **76**: 1137–1144.
- Zeraik AE & Nitschke M (2010) Biosurfactants as agents to reduce adhesion of pathogenic bacteria to polystyrene surfaces: effect of temperature and hydrophobicity. *Curr Microbiol* **61**: 554–559.
- Zinger-Yosovich KD, Iluz D, Sudakevitz D & Gilboa-Garber N (2010) Blocking of *Pseudomonas aeruginosa* and *Chromobacterium violaceum* lectins by diverse mammalian milks. *J Dairy Sci* **93**: 473–482.